Cyclothymic Disorder

Article written and reviewed by Dr Luca Moretti

Cyclothymic disorder, or cyclothymia, is a chronic disorder within the bipolar spectrum in which numerous periods of subthreshold hypomanic symptoms alternate with numerous periods of subthreshold depressive symptoms. The fluctuations must be persistent, recurrent and clinically significant, but they do not meet the requirements for full manic, hypomanic or major depressive episodes during the required diagnostic period.

Cyclothymia is not the same as normal temperamental variability and is not defined by a simple alternation between “good and bad days”. Diagnosis requires a prolonged course over time, with recognizable changes in mood, energy, sleep, activity, motivation and behavior associated with distress or impaired functioning.

In DSM-5-TR the minimum duration is two years in adults and one year in children and adolescents. During this interval, symptomatic periods must be present for at least half the time and symptom free intervals must not exceed two consecutive months. In ICD-11, cyclothymic disorder is classified among bipolar and related disorders with code 6A62.

Prevalence is difficult to estimate because symptoms are subthreshold, often do not directly lead people to seek care and can be confused with temperamental traits or personality disorders. Available estimates generally place lifetime prevalence at less than 1% in the general population, with values varying according to methodology.

Onset frequently occurs in adolescence or early adulthood and may be insidious. Late onset of previously absent affective fluctuations requires particular attention to substances, medications, neurological and endocrine conditions and other secondary causes.

Clinical relevance derives from chronicity. Even in the absence of major episodes, alternation between subthreshold activation and depression can interfere with relationships, education, work, financial decisions and continuity of projects. Some patients may subsequently develop full mood episodes and require diagnostic reclassification within the bipolar spectrum.

Etiology, Pathogenesis and Pathophysiology

No single cause of cyclothymic disorder is known. Available evidence is less extensive than for bipolar I and II disorders, but familial aggregation and nosological placement suggest a vulnerability partly shared with the broader bipolar spectrum.

A family history of bipolar disorder and other mood disorders is more common in people with cyclothymia than in the general population. This finding supports a genetic component, but there is no specific genetic profile capable of distinguishing cyclothymia, bipolar II disorder and temperamental variability in an individual.

Large genomic studies of bipolar disorder demonstrate a highly polygenic architecture, with numerous loci and genetic overlap with major depression and schizophrenia. It is plausible that some of this vulnerability also contributes to cyclothymia, but extrapolation from samples with major bipolar disorders must be performed cautiously.

The cyclothymic temperament described in the literature is not synonymous with a DSM-5-TR diagnosis of cyclothymic disorder. A temperamental trait may represent a vulnerability or affective phenotype, whereas the disorder requires specific criteria for duration, frequency, exclusion and clinical impairment.

Psychosocial stress, adverse events and sleep instability may modulate symptom expression in predisposed individuals. They are not, however, necessary or sufficient causes and should not be transformed into diagnostic criteria.

Circadian regulation represents a biologically plausible mechanism. Sleep, activity, hormonal secretion and mood are closely linked; irregularities in daily rhythms may accompany affective fluctuations and, in some patients, contribute to their destabilization.

Dopaminergic, serotonergic, noradrenergic, glutamatergic and GABAergic systems participate in regulation of mood and energy. There is no evidence, however, that cyclothymia is caused by a specific deficiency or excess of any one of these neurotransmitters.

Neuroimaging knowledge derives predominantly from studies of bipolar disorder as a whole. Mean alterations in prefrontal, limbic and striatal networks involved in reward and emotional regulation are not specific enough to be used as biomarkers of cyclothymia.

Similarly, studies of inflammation, oxidative stress, mitochondria and the hypothalamic pituitary adrenal axis have not identified specific diagnostic markers. The presence of group level abnormalities does not allow an individual pathophysiological mechanism to be assigned to a patient.

From a functional perspective, periods of subthreshold activation may involve increased energy, initiative, sociability and impulsivity; depressive periods may produce anhedonia, fatigue, pessimism and withdrawal. Repetition of these variations can produce instability of functioning even without major episodes.

Pathophysiology should therefore be interpreted as the result of a persistent affective vulnerability that interacts with sleep, stress and the environment. Diagnosis remains phenomenological and longitudinal, not biological.

Clinical Manifestations

The history should reconstruct the course of mood over months and years. The patient may report having “always had ups and downs”, but the clinician must turn this generic description into a chronology of periods with changes in energy, sleep, activity, self esteem, sociability and motivation.

During periods of subthreshold hypomanic symptoms, increased energy, reduced sleep, talkativeness, increased self esteem, greater goal directed activity, sociability, distractibility or impulsivity may occur. The number, duration or intensity, however, does not meet the requirements for a full hypomanic episode.

During subthreshold depressive periods, sadness, anhedonia, reduced energy, cognitive difficulties, insomnia or hypersomnia, low self esteem and pessimism may occur. Again, the presentation does not meet the full criteria for a major depressive episode.

The variations may be perceived as part of the person's character rather than as illness. For this reason, information from family members or partners, with the patient's consent, can be useful, particularly for understanding persistence of the pattern and its impact on functioning.

Reactivity to events does not exclude cyclothymia, but exclusively brief fluctuations determined by interpersonal conflicts require differential diagnosis with personality disorders and other conditions. Diagnosis should not be made on the basis of emotional lability alone.

During periods of activation, spending, impulsive decisions, increased sexual activity or conflicts may occur, but without the severity characteristic of mania. Concrete consequences should be explored because even subthreshold symptoms can cause cumulative harm.

During depressive periods, social withdrawal, reduced productivity and loss of motivation may predominate. Suicide risk cannot be ignored merely because symptoms do not reach the threshold for major depression; it should be assessed according to the actual presentation.

The clinical history should specifically investigate any previous major mood episodes. Documentation of true mania, hypomania or major depression changes the diagnostic framework and may make another bipolar or depressive spectrum diagnosis more appropriate.

Substance use, corticosteroids, stimulants, thyroid disorders and other conditions that can produce mood instability should be investigated. Primary cyclothymia should not be diagnosed when the pattern is attributable to the physiological effects of a substance or medical condition.

Comorbid anxiety disorders, ADHD, substance use and personality disorders can complicate the presentation. Their presence does not automatically exclude cyclothymic disorder, but requires determining which symptoms belong to an episodic affective pattern and which are persistent or reactive.

On mental status examination, the patient may be euthymic, mildly depressed or mildly activated depending on the time of the visit. A single interview is therefore insufficient to represent the disorder, which by definition requires a longitudinal assessment.

Mood diaries, sleep records and retrospective calendars may help document the pattern, provided they are interpreted within the clinical context. No diary pattern is pathognomonic.

Assessment and Diagnosis

Diagnosis is clinical and is based on longitudinal history. There are no blood tests or instrumental examinations that confirm cyclothymia. Before applying the criteria, it is necessary to establish whether full mood episodes have ever occurred and whether symptoms are better explained by substances, medical conditions or other psychiatric disorders.

Essential DSM-5-TR criteria for cyclothymic disorder

• For at least two years in adults or one year in children and adolescents, there are numerous periods with hypomanic symptoms that do not meet criteria for a hypomanic episode and numerous periods with depressive symptoms that do not meet criteria for a major depressive episode.
• During the required period, hypomanic and depressive symptoms are present for at least half the time and symptom free intervals do not exceed two consecutive months.
• Full criteria for a major depressive, manic or hypomanic episode have never been met.
• The symptoms are not better explained by schizophrenia spectrum disorders or other psychotic disorders.
• The symptoms are not attributable to the physiological effects of a substance or another medical condition.
• The presentation causes clinically significant distress or impairment in social, occupational or other important areas of functioning.

ICD-11 classifies cyclothymia under code 6A62 and describes a persistent pattern of mood instability with numerous periods of hypomanic and depressive symptoms insufficient for full episodes. ICD-11 and DSM-5-TR requirements are similar but should not be considered identical word for word.

Differential diagnosis with bipolar II disorder depends primarily on the presence of full hypomanic and major depressive episodes. Cyclothymia occupies the area of chronic subthreshold fluctuations; when major episodes emerge, the presentation must be reassessed according to the overall history.

Borderline personality disorder can produce intense and rapid affective instability. Distinction requires assessment of identity, relationships, fear of abandonment, self harm, a pervasive pattern and interpersonal reactivity, as well as the presence of relatively autonomous affective periods.

ADHD with impulsivity and emotional variability typically has a persistent neurodevelopmental course. Cyclothymic disorder instead requires recognizable affective fluctuations over time. The two conditions can coexist and one should not automatically be used to exclude the other.

Persistent depressive disorders are characterized by a predominantly depressive polarity rather than numerous periods of hypomanic symptoms. Anxiety disorders can instead produce insomnia and activation, but without the typical cyclothymic pattern.

Laboratory tests are selected according to clinical suspicion. TSH, complete blood count, electrolytes, liver and renal function tests or toxicology testing may be appropriate in specific patients, but they are used to assess alternative diagnoses or treatment safety.

Neuroimaging and EEG are not routinely indicated and are reserved for neurological signs, seizures, trauma, cognitive deterioration or other atypical features.

Scales such as the HCL-32 and dimensional mood instruments can support assessment, but they do not replace diagnostic criteria. Their use is particularly helpful for structuring the history, not for generating an automatic diagnosis.

Diagnosis should finally be accompanied by assessment of suicide risk, substance use, functioning, physical health, comorbidities and social support. Clinical severity does not depend solely on the absence of major episodes.

Treatment and Prognosis

Therapeutic evidence specific to cyclothymia is limited. There are no large randomized trial programs comparable to those available for bipolar I disorder or major depression, and no drug is approved exclusively for the treatment of cyclothymia.

The first intervention is an individualized clinical formulation. Predominant symptoms, frequency of fluctuations, risk, substance use, sleep disturbances and comorbidities should be identified. Treatment should not be selected solely on the basis of the diagnostic label.

Psychoeducation can help the patient recognize periods of activation and depression, identify prodromes and understand the importance of regular sleep, adherence and reducing destabilizing substances.

Psychotherapeutic interventions used in the bipolar spectrum, such as cognitive behavioral therapy, interpersonal and social rhythm therapy or interventions focused on emotional regulation, can be used according to individual characteristics. Direct evidence for cyclothymia remains less robust than for major bipolar disorders.

When instability is clinically significant, some clinicians use mood stabilizers such as lithium, lamotrigine or valproate based on extrapolation from the bipolar spectrum and the individual presentation. Selection must be cautious because specific evidence is limited and these medications carry risks and require monitoring.

Antidepressants require caution. In a disorder within the bipolar spectrum they may promote activation or destabilization in some patients; they should not be prescribed automatically for every subthreshold depressive phase.

Management of sleep is particularly important. Regular schedules, reduction of sleep deprivation and treatment of insomnia can reduce destabilizing factors, although they do not represent a specific cure for the disorder.

Alcohol, cannabis and stimulants can increase lability, impulsivity and sleep disturbances. Reducing or treating problematic substance use is therefore a substantial component of the clinical strategy.

Prognosis is variable. Some people maintain a cyclothymic pattern for years, others achieve periods of stability, and some subsequently develop hypomanic, manic or major depressive episodes sufficient to change the diagnosis.

It is not possible to predict with certainty which patients will progress to bipolar I or II disorder. Family history, severity, early onset and comorbidities may indicate greater vulnerability but are not deterministic prognostic tools.

Appropriate treatment can reduce symptoms, impulsivity and impairment and improve quality of life. It has not been demonstrated that a specific therapy can reliably prevent the subsequent onset of a major bipolar disorder.

Complications

The main consequence of cyclothymia is chronic functional impairment. Repeated fluctuations can disrupt academic and occupational performance, relationships and projects even when no single period reaches the threshold for a major episode.

Impulsivity during activated periods can lead to spending, conflicts, substance use or risky behaviors. Severity may be lower than in mania, but repetition over time can produce significant consequences.

Depressive periods can be associated with isolation, loss of motivation and suicidal ideation. Suicide risk should be assessed on the basis of actual symptoms and comorbidities, not inferred solely from the diagnostic category.

Anxiety disorders and substance use can increase instability and worsen functioning. Comorbidities should be treated in an integrated manner.

One possible course is the onset of full mood episodes, requiring reassessment of the diagnosis toward bipolar I disorder, bipolar II disorder or another appropriate category. This possibility justifies longitudinal follow up.

The risk of misdiagnosis is relevant. Interpreting cyclothymia as mere temperament may delay treatment, whereas diagnosing cyclothymia in the presence of nonepisodic affective lability may lead to inappropriate therapies.

Adverse effects of treatment can become a source of morbidity if mood stabilizing drugs are used without an adequate indication or monitoring. The benefit risk balance should be reassessed over time.

Optimal management therefore requires continuity of care, monitoring of the course and attention to functioning, safety and comorbidities, without treating a subthreshold diagnosis as a clinically negligible condition.

Bibliography
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association Publishing; 2022.
2. World Health Organization. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. World Health Organization; 2024.
3. Yatham LN et al. Canadian Network for Mood and Anxiety Treatments and International Society for Bipolar Disorders 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. 20(2), 2018: 97-170.
4. Keramatian K et al. The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus. 21(4), 2023: 344-353.
5. McIntyre RS et al. Bipolar disorders. The Lancet. 396(10265), 2020: 1841-1856.
6. McIntyre RS et al. The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management. World Psychiatry. 21(3), 2022: 364-387.
7. Carvalho AF et al. Bipolar disorder. New England Journal of Medicine. 383(1), 2020: 58-66.
8. O’Connell KS et al. Genomics yields biological and phenotypic insights into bipolar disorder. Nature. 639, 2025: 968-975.
9. Mullins N et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics. 53(6), 2021: 817-829.
10. Ching CRK et al. What we learn about bipolar disorder from large-scale neuroimaging: findings and future directions from the ENIGMA Bipolar Disorder Working Group. Human Brain Mapping. 43(1), 2022: 56-82.
11. Van Meter AR et al. Cyclothymic disorder: A critical review. Clinical Psychology Review. 32(4), 2012: 229-243.
12. Perugi G et al. Diagnosis and Treatment of Cyclothymia: The “Primacy” of Temperament. Current Neuropharmacology. 15(3), 2017: 372-379.
13. Singh B et al. Bipolar disorder. The Lancet. 406(10506), 2025: 963-978.
14. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline CG185. National Institute for Health and Care Excellence; 2014, updated 2025.
15. Department of Veterans Affairs et al. VA/DoD Clinical Practice Guideline for the Management of Bipolar Disorder. Version 2.0. Department of Veterans Affairs and Department of Defense; 2023.